Assignee
XIGEN INFLAMMATION LTD
CY·8 granted patents·13 pending applications·16 citations·filing 2012–2022
Top patents by PatentIndex Score
21 records- 0190US9624267B2JNK inhibitor moleculesXIGEN INFLAMMATION LTD·Filed 2015·Granted Apr 18, 2017·5 cites·11 claims
- 0286US9610330B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2015·Granted Apr 4, 2017·5 cites·14 claims
- 0385US9290538B2Cell-permeable peptide inhibitors of the JNK signal transduction pathwayXIGEN INFLAMMATION LTD·Filed 2013·Granted Mar 22, 2016·5 cites·18 claims
- 0476US10596223B2JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2016·Granted Mar 24, 2020·1 cites·5 claims
- 0569US2022280591A1Use For JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2022·Application pending·0 cites
- 0666US2020062805A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2019·Application pending·0 cites
- 0760US2017320917A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2017·Application pending·0 cites
- 0859US2015133393A1Novel JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 0959US2020206301A1JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2020·Application pending·0 cites
- 1056US11779628B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2015·Granted Oct 10, 2023·0 cites·1 claims
- 1156US2016264630A1Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction PathwayXIGEN INFLAMMATION LTD·Filed 2016·Application pending·0 cites
- 1255US10967038B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2018·Granted Apr 6, 2021·0 cites·2 claims
- 1354US2016115200A1New Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2014·Application pending·0 cites
- 1452US2019337988A1Novel transporter constructs and transporter cargo conjugate moleculesXIGEN INFLAMMATION LTD·Filed 2018·Application pending·0 cites
- 1549US10624948B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2014·Granted Apr 21, 2020·0 cites·8 claims
- 1645US11331364B2Use for JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2019·Granted May 17, 2022·0 cites·17 claims
- 1745US2014309400A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye SyndromeXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 1844US2017128516A1Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 1943US2016089413A1Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 2038US2017137481A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 2136US2018170983A1New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive ImpairmentXIGEN INFLAMMATION LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XIGEN INFLAMMATION LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →